Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis  by Amdur, Richard L. et al.
Outcomes following diagnosis of acute renal failure
in U.S. veterans: focus on acute tubular necrosis
Richard L. Amdur1,2, Lakhmir S. Chawla3,4, Susan Amodeo1,5, Paul L. Kimmel3,6 and Carlos E. Palant1,3
1Research and Medical Service, Veterans Affairs Medical Center, Washington, District of Columbia, USA; 2Department of Psychiatry,
Georgetown University School of Medicine, Washington, District of Columbia, USA; 3Division of Renal Diseases and Hypertension,
Department of Medicine, George Washington University Medical Center, Washington, District of Columbia, USA; 4Department of
Anesthesiology and Critical Care Medicine, George Washington University Medical Center, Washington, District of Columbia, USA;
5Decision Support Systems, Fiscal Service, Veterans Affairs Medical Center, Washington, District of Columbia, USA and 6Division of
Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health,
Bethesda, Maryland, USA
When patients develop acute kidney injury, a small fraction
of them will develop end-stage renal disease later. The
severity of renal impairment in the remaining patients is
uncertain because studies have not carefully examined renal
function over time or the precise timing of entry into a late
stage of chronic kidney disease. To determine these factors,
we used a United States Department of Veterans Affairs
database to ascertain long-term renal function in 113,272
patients. Of these, 44,377 had established chronic kidney
disease and were analyzed separately. A cohort of 63,491
patients was hospitalized for acute myocardial infarction
or pneumonia and designated as controls. The remaining
5,404 patients had diagnostic codes indicating acute renal
failure or acute tubular necrosis. Serum creatinine, estimated
glomerular filtration rates, and dates of death over a
75-month period were followed. Renal function deteriorated
over time in all groups, but with significantly greater severity
in those who had acute renal failure and acute tubular
necrosis compared to controls. Patients with acute kidney
injury, especially those with acute tubular necrosis, were
more likely than controls to enter stage 4 chronic kidney
disease, but this entry time was similar to that of patients
who initially had chronic kidney disease. The risk of death
was elevated in those with acute kidney injury and chronic
kidney disease compared to controls after accounting for
covariates. We found that patients who had an episode of
acute tubular necrosis were at high risk for the development
of stage 4 disease and had a reduced survival time when
compared to control patients.
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Acute kidney injury (AKI), a term that is increasingly used to
describe acute renal failure (ARF),1 is an ominous diagnosis
that complicates the hospital course of patients by exposing
them to circulatory overload, hyperkalemia, metabolic
acidosis, and neurological complications, as well as to an
increased mortality risk.2–6 In spite of recent improve-
ments, the mortality of AKI remains unacceptably high.6,7
As a result of AKI, patients experience an increased length of
stay and may require dialysis. The incidence of AKI is
increasing, and will nearly double over the next decade as the
population ages.7–9 Population-based studies show that even
small acute changes in serum creatinine concentration (SC)
are associated with poor outcomes.10–12 After accounting
for other predictors, AKI is an independent risk factor for
death.13,14
The relationship between AKI and chronic kidney
disease (CKD) has not been well studied. When risk factors
for AKI are assessed, CKD is found to be a significant and
consistent risk for the development of AKI.15,16 Obser-
vational studies show that AKI superimposed on CKD
leads to end-stage renal disease (ESRD) at a higher frequency
than does AKI alone.7,16,17 However, whether AKI causes
CKD is unknown. Several reasons justify a closer examination
of the natural history of AKI. The United States and
several European and Asian countries are affected by a rising
incidence of ESRD,8 but the relative contribution of AKI
to this problem has not been adequately measured. Patients
who develop AKI may require specialized continuous
surveillance, as well as rigorous avoidance of potentially
nephrotoxic drugs and interventions that may hasten
progression to late stages of CKD. Close follow-up of the
post-AKI period should help identify and treat emerging
risk factors that impede renal recovery. As reported in
the United States Renal Data System, only 16.3% of
patients who were hospitalized for AKI were followed
by a nephrologist after discharge, and were otherwise less
likely to receive preventive care such as monitoring of
HgbA1c levels in diabetes mellitus and presence of micro-
albuminuria.8
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Within the spectrum of AKI, acute tubular necrosis (ATN)
is a condition with distinctive clinical and histological
characteristics, and is one of its most common causes in
hospitalized patients.18–20 It is usually and selectively
diagnosed by nephrologists and by critical care physi-
cians,4,21,22 and thus may be underrepresented as a cause of
AKI outside the ICU. Although some affected patients with
ATN require dialysis, and a small proportion of patients may
progress to ESRD, the course for the majority of patients
after discharge has been thought to include a full restoration
of renal function.21,22 Although there have been a few
studies of individual patient outcomes23,24 and single center
studies21 after the development of ATN, there are no long-
term serial laboratory and epidemiological data regarding its
outcome.25
To test the hypothesis that AKI, and specifically ATN,
causes CKD, we reviewed a large database of patients enrolled
in the health-care facilities of the Department of Veterans
Affairs (VA) between October 1999 and December 2005,
using longitudinal follow-up of laboratory values. We also
examined the impact of ATN on long-term mortality rates.
RESULTS
Sample characteristics
A total of 113,272 patients met entry criteria (Table 1,
Figure 1). Patients were 2.2% women, 74.4% Caucasian,
18.3% African American, 5.6% Hispanic, 0.8% Hawaiian-
Pacific Islander, 0.6% Native American, and 0.4% Asian, with
a mean age of 70.8±11.8 years. There were 3,506,131 SC
readings across all patients, with a median of 22 readings per
patient. There were 63,491 CON patients, 346 ATN patients,
5058 ARF patients, and 44,377 CKD patients. A higher-than-
expected number of women were in the ATN group and a
lower-than-expected number in the ARF group. A higher-
than-expected number of African Americans were in the ARF
and ATN groups, whereas a lower-than-expected number of
Caucasians were in the ARF group. ATN patients were the
youngest, followed by ARF, with CKD patients being the
oldest. The mean hospital length of stay was 7.5±20.3 days,
and did not differ significantly across groups.
Change in SC after diagnosis
The CON, ATN, and ARF patients had a mean preadmission
SC level of 1.0–1.1 mg/dl and an estimated glomerular
filtration rate (eGFR) of 80–85 ml/min per 1.73 m2 (Figures
2a and b). Prediagnosis SC and eGFR values for ATN and
ARF patients were not significantly different. As expected,
CKD patients had a significantly higher preadmission SC and
a lower eGFR than did other groups. From admission to 30
days later, the mean SC values increased sharply for ATN (by
245%) and ARF (by 130%) patients to 3.9 and 2.6 mg/dl,
respectively. During this period, mean SC also increased
significantly for CKD and CON patients, but less sharply (by
22 and 5% to mean values of 2.7 and 1.1 mg/dl, respectively).
As assessed by RIFLE criteria, the incidences of R, I, and F
stages were 16.4, 26.0, and 51.9% (ARF), 6.7, 11.6, and 78.3%
(ATN), and 19.3, 4.0, and 2.2% (CON), respectively. During
the month after admission, mean peak SC readings were
(in mg/dl) 4.69±3.4 for ARF, 6.45±3.9 for ATN, 3.56±2.9
for CKD, and 1.29±0.7 for CON. After admission, the mean
eGFR of ARF and ATN patients remained significantly below
CON (Bonferroni-corrected Po0.05). The mean SC values of
all four groups remained elevated above their preadmission
means across all follow-up time periods (Bonferroni-
corrected Po0.05). As a percentage of baseline eGFR, the
declines in mean eGFR during 31–90 days, 91–365 days, and
41 year after diagnosis were 19, 14, and 14% for ATN
patients, 12, 10, and 11% for ARF patients, 2, 4, and 6% for
CON patients, ando2% change at any time period for CKD
patients.
Across the five time periods, there was a significant
difference among the four diagnostic groups in the slope of
both SC (Po0.0001) and eGFR (Po0.0001). Both ATN
and ARF patients had a larger eGFR decline than did
either CON or CKD patients, from preadmission to each of
the subsequent time periods (all Po0.01 after Bonferroni’s
correction). CKD patients had a larger eGFR decline than
did CON patients from before to 1 month after diagnosis,
but a significantly smaller eGFR decline than did CON
patients from before admission to each of the later time
periods.
Table 1 | Patient demographics
Diagnosis
n
% Of sample
ATN
346
0.3
ARF
5058
4.5
CON
63,491
56.1
CKD
44,377
39.2
Agea (mean±s.d.) 63.8±12.5 66.5±12.2 68.7±11.9 74.4±10.6
Gendera (% female) 4.1 1.8 2.1 2.3
LOS for index admission (mean±s.d.) 7.7±11.4 7.5±15.9 7.5±20.3 7.5±20.8
No. of SC readings during 12 months pre-admissiona (mean±s.d.) 10.9±16.3 10.1±13.7 6.4±9.6 10.4±14.0
Race,a n (% of diagnostic group)
African American 80 (23.1) 1592 (31.5) 12,340 (19.5) 6665 (15.1)
Caucasian 240 (69.4) 3063 (60.6) 46,606 (73.6) 34,162 (77.1)
Hispanic 18 (5.2) 321 (6.4) 3365 (5.3) 2592 (5.9)
Asian 2 (0.6) 11 (0.2) 181 (0.3) 198 (0.5)
Hawaian/Pacific Islander 2 (0.6) 44 (0.9) 430 (0.7) 367 (0.8)
Native American 4 (1.2) 24 (0.5) 396 (0.6) 300 (0.7)
ARF, acute renal failure; ATN, acute tubular necrosis; CKD, chronic kidney disease; CON, control; LOS, length of stay; PNE, pneumonia; SC, serum creatinine.
aDifferences across diagnostic groups are significant (Po0.0001).
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Impact of diagnosis and other covariates on renal outcome
and mortality
Admission date to CKD-4. There were 112,292 patients
with data for all variables who were eligible for survival
analyses. A total of 6514 CKD patients who entered CKD
stage 4 (CKD-4) or higher before their diagnosis date were
excluded from this analysis. Of the remaining patients, 11.4%
reached CKD-4, including 20.0% of ATN, 13.2% of ARF,
24.7% of CKD, and 3.3% of CON patients. Differences in the
proportion reaching CKD-4 between every pair of groups,
except the ATN and CKD groups, were significant (Po0.01).
There was a significant difference in the time from diagnosis
to development of CKD-4 across groups (Po0.0001)
(Table 2, Figure 3). After controlling for other variables,
having an ARF, ATN, or CKD diagnosis increased the risk of
developing CKD-4 by 303, 564, and 550%, respectively,
compared with CON patients (Table 2, Figure 3). Other
significant covariates included age (0.9% increase in risk of
CKD-4 for each additional year of age; Po0.0001), diabetes
mellitus (32.7% increased risk of CKD-4; Po0.0001), mean
preadmission SC (19% increased risk of CKD-4 for
each additional 1.0 mg/dl; Po0.0001), mean preadmission
albumin concentration (53% reduction in risk for each
additional 1.0 mg/dl; Po0.0001), and teaching hospital
status (16% increased risk of CKD-4; Po0.0001). All ATN
patients who entered CKD-4 did so within 20 months of
diagnosis, whereas in the other groups, patients continued to
develop CKD-4 for up to 5 years (Figure 3). At 6 months
after diagnosis, a higher proportion of ATN patients entered
CKD-4 compared with CON (Po0.0001) and ARF patients
(Po0.01), but not compared with CKD patients. The
percentage reaching CKD-4 was different (Po0.05) across
the ARF, CON, and CKD groups at 10, 20, 30, 40, and 50
months after diagnosis, but was not different between
ATN and CKD patients at 10 months. An ATN  Time
interaction term added to account for the nonproportional
hazard for ATN was significant (Po0.001), but its addition
did not change other hazard ratios, except that of ATN,
which increased from 6.4 to 10.3.
Test for bias due to missing SC readings. At 1–3 months
after admission, the mean numbers of SC readings per month
(and the percentage of subjects who had readings) for ARF,
Subjects in DSS database with ATN/ARF/AMI/PNE admission during study period: 147,226
Primary diagnosis included both
ATN/ARF and PNE/MI → drop 3670
Missing pre-diagnosis
SC readings
In CKD stage 3 or greater
in the year prior to
diagnosis
Missing covariate data
Subjects available for
survival analysis: ATN
345
ARF
5021
37
ATN
346
ARF
5058
197 3638
8882
2707
CON
122,020
27,411
15,781
15,337
CON
63,491
641
CON
62,850
CKD
44,076
CKD
44,377
19,172 to CKD
25,205 to CKD
DROP
30,284
301
542
166
ATN
1251
ARF
20,285
1
Subjects available for
repeated measures
analysis:
Mean pre-diagnosis
eGFR < 60 ml/min per 1.73m2
Figure 1 |Patient flowchart. ARF, acute renal failure; ATN, acute tubular necrosis; CKD, chronic kidney disease; CON, control; eGFR,
estimated glomerular filtration rate; MI, myocardial infarction; PNE, pneumonia; SC, serum creatinine.
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ATN, CON, and CKD were 1.5 (57%), 2.1 (64%), 1.0 (57%),
and 1.6 (48%), respectively. At 3–12 months after admission,
the corresponding numbers were 2.7 (64%), 2.6 (66%), 2.2
(63%), and 3.2 (66%). After 12 months, the numbers were
3.3 (43%), 3.3 (45%), 3.7 (43%), and 4.3 (51%). The results
of Cox regression using only subjects who had at least one
SC reading at each time period were similar to the results
using all subjects; after accounting for covariates, ATN
raised the risk of entering CKD-4 by 815% and ARF raised
this risk by 364% (both Po0.0001), compared with the risk
in controls.
Diagnosis date to death. In all, 50,251 (44.7%) patients
died during the study period (Table 3). Diagnosis was
significantly associated with differential time to death
(Po0.0001) (Figure 4). Patients with ATN or ARF died at a
rate similar to CON (approximately 37–39%), whereas CKD
patients died at a higher rate (53.4%; Po0.01). The median
time to death was 51 months for CON, 57 months for ATN,
44 months for ARF, and 24 months for CKD patients. After
controlling for covariates, patients with ARF and CKD had
increased risk of death of 12 and 20%, respectively, compared
with CON patients (Po0.0001). CON, ARF, and CKD groups
had different survival rates at 10, 20, 30, 40, and 50 months
after diagnosis (with CON4ARF4CKD). For ATN patients,
the likelihood of surviving overlapped with that of the ARF
group at 10–30 months after admission, and with that of CON
patients at 40 and 50 months (Figure 4).
Diagnosis date to combined end point. Of the patients,
46% reached the combined end point during the study
period (Table 4; approximately 40–41% of patients in the
ARF, ATN, and CON groups, 58.2% of patients in the CKD
group; Po0.01). The median time to the combined end
point was 20, 40, 50, and 51 months for CKD, ARF, ATN, and
CON patients, respectively (Po0.0001). After accounting for
covariates, patients with ARF, ATN, and CKD had increased
risk of reaching the combined end point of 14% (Po0.0001),
23% (Po0.05), and 35% (Po0.0001), respectively, com-
pared with CON patients. At 10, 20, 30, 40, and 50 months
after diagnosis, ARF patients had a consistently higher
probability of reaching the combined end point than did
CON patients and a lower probability than did CKD patients,
whereas the probability for ATN fluctuated, being more likely
than ARF at 20 months and less likely at 50 months to reach
this end point (Figure 5).
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Figure 2 | (a) Mean serum creatinine during five time periods,
classified by patient type. Error bars show 95% confidence
interval. (b) Mean eGFR classified by group by time, with 95%
confidence interval. ARF, acute renal failure; ATN, acute tubular
necrosis; CKD, chronic kidney disease; CON, control; eGFR,
estimated glomerular filtration rate.
Table 2 | Survival analysis results: time from diagnosis to development of CKD-4
Diagnosis Total, na
Developed
CKD-4
% Patients
developing CKD-4*
Survival time,b 20th
percentile months (95% CI)
Cox regression
hazard ratio
ATN 345 69 20.0x 10.9 (4.0–28.0) 6.64**
ARF 5021 663 13.2y 57.0 (44.5–68.0) 4.03**
CON 62,850 2100 3.3z —c 1.00
CKD 37,562 9263 24.7x 11.5 (11.0–13.0) 6.50**
Total 105,778 12,095 11.4
ARF, acute renal failure; ATN, acute tubular necrosis; CI, confidence interval; CKD-4, chronic kidney disease stage 4; CON, control; DM, diabetes mellitus; SC, serum creatinine.
aNo. of cases for each group differs slightly from Tables 2 and 4 because patients with missing data for any of the covariates were dropped from Cox regression, and those
who entered CKD-4 before diagnosis were dropped from Cox and Kaplan–Meier analyses for time to CKD4.
bSurvival time in number of months from diagnosis date to development of CKD Stage 4. The 20th percentile indicates the number of months for 20% of the patients to
develop CKD-4. For ARF the upper limit of the 95% confidence interval was estimated by extrapolating from the table of Kaplan–Meier survival estimates.
cThe 20th percentile for survival time could not be estimated for CON because in this group only 3% of patients ever developed CKD-4.
*Percentages with similar superscripts beside them are not significantly different (w2-test Po0.01).
**Po0.0001.
Patients who entered CKD-4 before their diagnosis date were excluded from this analysis. Cox regression covariates were ARF, ATN, CKD, age, Caucasian, African American,
Hispanic, gender, pre-admission DM, diagnosis date, mean pre-admission serum creatinine, mean pre-admission albumin, and teaching hospital (y/n).
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DISCUSSION
To examine the association between a diagnostic-coded
episode of ARF or ATN and long-term renal function and
mortality in patients without preexisting renal failure, we
reviewed a large national database of subjects enrolled in the
health-care facilities of the US Department of VA between
1999 and 2005. We used available laboratory data to follow
SC and eGFR over time. As a control group, we assessed the
renal function of hospitalized patients who, during the same
period, were diagnosed with either pneumonia (PNE) or an
acute myocardial infarction (MI) but not with ARF or ATN.
From the sample, we excluded patients who had CKD before
the diagnosis of PNE, MI, ARF, or ATN. We also compared
the development of late-stage CKD, the need for dialysis, as
well as the mortality rates of patients with ARF, ATN, PNE
and MI with those of CKD patients. Our results indicate that
ARF and ATN are associated with a significant decline in
renal function over time after hospital discharge. These
findings suggest that survivors of AKI are more likely than
controls to progress to late-stage CKD. The results provide
support for the data of Hsu et al.,9 who noted that the
incidence of ESRD cannot be solely linked to the prevalence
of CKD. In short, AKI may be an important cause of CKD.
A total of 20% of survivors of ATN progressed rapidly to
CKD-4. Having a diagnosis of ATN in a patient with a
previously normal renal function was associated with a time
to development of CKD-4 that was comparable with that of
early-stage CKD patients. In all, 13.2% of patients with ARF
developed CKD-4. The mortality rates for the ATN, ARF, and
CON groups were similar, but were exceeded by that of the
CKD group. These findings underscore the significant public
health hazard of developing AKI and the high mortality
associated with CKD.
Prospective and retrospective studies have addressed the
global long-term effects of ARF and ATN on renal function.
Most,22 but not all,21 such studies have been in single centers,
and many may have included patients with preexisting renal
disease.21,22,26,27 In several of these studies, the emphasis was
on the need for renal replacement therapies at various times
after either ICU or hospital discharge, whereas lesser degrees
of renal impairment did not receive attention. Previous work
has been difficult to perform, because longitudinal laboratory
data on such a survivor set have been unavailable, and
patients are often not followed by nephrologists after
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Figure 3 |Kaplan–Meier survival estimates for time (months)
from diagnosis to entry into CKD-4, classified by patient type.
CKD patients who entered CKD-4 before their diagnosis date were
excluded. ARF, acute renal failure; ATN, acute tubular necrosis;
CKD, chronic kidney disease; CKD-4, CKD stage 4; CON, control.
Table 3 | Survival analysis results: time from diagnosis to death
Diagnosis Total, n Died Percent died* Survival time, median months (95% CI) Cox regression hazard ratio
ATN 345 127 36.8a 56.7 (38.9–77.0)a 1.10
ARF 5021 1958 39.0a 43.8 (40.5–47.3) 1.12**
CON 62,850 24,622 39.2a 51.3 (50.2–52.4) 1.00
CKD 44,076 23,544 53.4b 24.1 (23.5–24.8) 1.20**
Total 112,292 50,251 44.7
ARF, acute renal failure; ATN, acute tubular necrosis; CI, confidence interval; CON, control; DM, diabetes mellitus.
aFor ATN, median and upper bounds were estimated based on extrapolation from Kaplan–Meier lifetable.
*Percent mortality with similar superscript letters are not significantly different (w2-test Po0.01).
**Po0.0001.
Cox regression covariates were ARF, ATN, CKD, age, Caucasian, African American, Hispanic, gender, DM, diagnosis date, pre-admission mean serum creatinine,
mean pre-admission albumin, and teaching hospital (y/n).
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Figure 4 |Kaplan–Meier survival estimates for time (months)
from diagnosis to death, classified by patient type. ARF, acute
renal failure; ATN, acute tubular necrosis; CKD, chronic kidney
disease; CON, control.
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discharge. The lack of a long-term comparison with a
medically ill control group (that is, acutely ill patients
without renal impairment) in the majority of previous
studies does not address the fact that AKI occurs in a
predominately aging population that may be prone to
declining renal function regardless of the effect of intervening
acute renal insults.28 Uchino et al.5 in a large prospective
multinational study of Intensive Care Unit patients with ARF
found that, at hospital discharge, 86% were dialysis
independent, but no information was provided regarding
the renal function of the surviving population. Schiffl22
prospectively followed a group of 433 consecutive patients
diagnosed with ATN on the basis of clinical and laboratory
findings. At discharge, recovery of renal function was
complete in 57% of surviving patients, 33% had mild-to-
moderate renal failure (SC41.3 but o3 mg/dl), and 10%
had SC values between 3 and 6 mg/dl but did not require
dialysis. At 1 year after discharge, 35% of the initial cohort
was reevaluated. Only one patient progressed to ESRD. It is
unclear whether surviving patients had persistent CKD, but
they did not reach ESRD. In a study of 187 consecutive
patients diagnosed with ATN in Spain between 1977 and
1992, complete recovery of renal function was documented in
81% of patients. Liano et al.21 assessed the long-term
outcome of ATN and reviewed studies that assessed the
long-term outcomes of ATN. They found a variable incidence
of CKD between 2 and 48% in surviving ATN patients using
varying definitions.21 A recent meta-analysis indicated that a
higher proportion of elderly survivors with an episode of AKI
did not recover renal function compared with younger
controls.14
Even mild episodes of AKI are associated with increased
mortality.10 The relationship between AKI and mortality
seems to be independent of coexisting medical condi-
tions.10,14 In a multinational study in over 100,000 critically
ill patients, those with AKI had an inpatient mortality of
27–33%.29 As many patients with AKI will not live long
enough to develop either CKD or ESRD, studies addressing
the long-term health consequences of ARF and ATN should
not only consider their impact on renal function but should
also examine their long-term posthospitalization mortality
rates when compared with an appropriately medically ill
control group. We chose patients who suffered from an
episode of PNE or MI as controls because these are also in
most instances acute, reversible insults with significant
hemodynamic and systemic inflammatory components that
require hospitalization, in itself a risk for undiagnosed renal
insult (through the use of contrast, nephrotoxic medications
and other medical interventions). Thus, we sought to control
for the effects of hemodynamic and inflammatory influences
and hospital-related adverse effects on long-term renal
prognosis, independent of a diagnosis of AKI. The data
suggest that, compared with controls, patients diagnosed
with AKI have an additional disease burden that results in an
increase in CKD rates. Phenotypic diagnosis of ARF/ATN was
associated with meaningful renal outcomes and not just
hospitalization for a life-threatening illness.
A limitation of this study is a lack of linkage between
individual patients with ARF or ATN, and entry into the US
ESRD program. However, the United States Renal Data
System data indicate that patients hospitalized for ARF were
more likely to die in the months after discharge than to
develop ESRD,8 although comparisons with similarly aged
control groups were not reported. A recent study confirmed
Table 4 | Survival analysis results: time from diagnosis to combined end point (the earliest of CKD-4, chronic dialysis, or death)
Diagnosis Total, n Combined outcome Percent combined outcome* Survival time, median months (95% CI) Cox regression hazard ratio
ATN 345 143 41.4a 49.5 (28.5–61.0)a 1.23w
ARF 5021 2051 40.8a 39.8 (37.4–43.4) 1.14**
CON 62,850 24,821 39.5a 50.5 (49.5–51.5) 1.00
CKD 37,296 21,702 58.2b 19.7 (19.2–20.2) 1.35**
Total 105,512 48,717 46.2
ARF, acute renal failure; ATN, acute tubular necrosis; CI, confidence interval; CON, control; DM, diabetes mellitus.
aUpper bound estimate of the 95% CI for ATN was estimated by extrapolation using the Kaplan–Meier lifetable.
*Percent mortality with similar superscript letters are not significantly different (w2-test Po0.01).
**Po0.0001.
wPo0.05.
Patients who entered CKD-4 or started chronic dialysis before their diagnosis date are excluded from this analysis. Cox regression covariates were ARF, ATN, CKD, age,
Caucasian, African American, Hispanic, gender, DM, diagnosis date, mean pre-admission serum creatinine, mean pre-admission albumin, and teaching hospital (y/n).
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Figure 5 |Kaplan–Meier survival estimates for time (months)
from diagnosis to combined end point (the earliest of CKD-4,
chronic dialysis, or death), classified by patient type. ARF,
acute renal failure; ATN, acute tubular necrosis; CKD, chronic
kidney disease; CKD-4, CKD stage 4; CON, control.
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that in a Medicare database, only 3.7% of patients with AKI
progressed to ESRD over a 2-year follow-up period.16
Nevertheless, CKD has been shown to be an important
independent predictor of morbidity and mortality.30,31
Therefore, progression to CKD-4 is an important end point.
The small number of women in the VA database should be
noted. Epidemiological data suggest a higher prevalence of
AKI in men compared with women,16 consistent with a
greater prevalence of and susceptibility to CKD in men.32
Kim et al.33 also showed a role for male sex hormones in the
pathogenesis of AKI in a model using castration, further
suggesting that men are a high-risk group. Future studies,
however, should include more representative populations of
the genders.
Information regarding mortality rates must be interpreted
with caution because the sources of information have less
than 100% sensitivity. The BIRLS (Beneficiary Identification
and Records Locator Subsystem) Death File has a sensitivity
estimated at 77.4% and the sensitivity of the Social Security
Administration Death Master File has been rated at 92.1%
compared with that of the National Death Index.34 Thus, using
a combination of SSA Death File and BIRLS improved our
ability to detect deaths in all groups. We do not, however,
expect that failure to capture all deaths differentially would
affect the ARF, ATN, and control groups, or that it would have
affected the time to death for any particular diagnostic group.
Although the specificity of the ICD-9-CM diagnosis of
ARF is quite high (on the order of 99%), earlier reports
indicated low sensitivity (between 17.4 and 19.2 %) when
validated against SC readings.6 This could mean that
potential cases of AKI are missed and could end up in the
control group. However, potential bias in such cases would be
toward null in estimates of relative mortality risk, and the
coding should be of use in comparing long-term mortality
outcomes of patients with and without AKI.6 Low sensitivity
could lead to underestimating the true incidence of ATN and
ARF, and the relative risk (compared with controls) of AKI
progressing to CKD. As our data set is deidentified, we do not
have the capacity to interrogate individual patient charts and
assess the precision of ARF and ATN as clinical diagnoses.
However, our finding that 494% of patients coded for ATN
and ARF had a RIFLE score of ‘R’, and that450% achieved a
score of ‘I’, suggests that our specificity was quite high. The
fact that 25.5% of CON patients met the ‘R’ criterion suggests
that our sensitivity (74.5%) was much higher than that in
previous database-oriented studies.6 Moreover, ATN as coded
in this cohort is clearly a more severe form of AKI compared
with the ARF group on the basis of RIFLE scoring and peak
SC. As our goal in this study was to compare subjects
diagnosed with ATN and ARF with demographically similar
patients who had similar acute admissions, we excluded
patients with CKD on the basis of eGFR and SC values. Our
conclusions are therefore likely to be reliable, but may
underestimate the risk of ATN progressing to CKD,
compared with acutely ill patients of similar demographics
without AKI, and may represent conservative estimates of the
magnitude of associations between AKI and CKD. Further-
more, it should be noted that small (B0.3 mg/dl) SC
increases may occur for a variety of reasons other than
AKI; thus, meeting the ‘R’ criterion is not synonymous with
having AKI.26 The estimates of GFR in this study must be
evaluated with caution, as they were not calibrated with
Cleveland Clinic gold standards.35
The unique strengths of this study include the longitudinal
nature of assessments in a large, representative national
database, including serial evaluations of both SC and eGFR,
allowing the natural history of ATN to be assessed and the
staging of development and progression of CKD to be
performed. In addition, we analyzed this data set using SC
and eGFR separately. The diagnosis of ATN is likely to be
highly specific, and the finding that the progression to late-
stage CKD, at a rate similar to that of CKD patients, is novel
and important for health policy planners and primary
physicians following patients with ATN after hospital dis-
charge. Such a follow-up could be an opportunity for the
primary prevention of the progression of CKD. In addition, we
excluded patients with preexisting CKD, which was not carried
out in the majority of previous studies, and studied an
appropriately medically ill, hospitalized comparison group.
Although recent work has emphasized the poor outcome
of CKD patients with regard to mortality and progression to
ESRD,31 this study shows that the relative risk of mortality in
survivors of AKI and of progression to CKD-4 is comparable
in patients with ATN and CKD. The relationship between
AKI episodes and development of CKD is plausible because
of the factors that enhance progression of renal dysfunction
in patients with diminished renal reserve.36–38 If patients with
AKI have diminished, abnormal renal function over time, or
lack of renal reserve, it is reasonable to assume that measures
such as control of hypertension and use of agents that
interrupt the renin–angiotensin–aldosterone system may be
effective in maintaining renal function and in forestalling
progression of CKD.37,38 We hypothesize that this would
decrease the rate and incidence of progression to CKD. The
current lack of surveillance and interventional strategies in
this population may pose public health issues. The growth of
the population of AKI patients increases the urgency of
devising surveillance and care strategies to diminish the
incidence of CKD and ESRD.
MATERIALS AND METHODS
Patients
We selected all patients in the VA Decision Support System database
with at least one inpatient admission with a primary diagnosis of
ARF (codes 584.xx except 584.5) or ATN (code 584.5) as markers
for an episode of AKI. Patients with PNE (ICD-9 code 486.xx) or
MI (codes 410.xx) were designated as our control (CON) group.
The study period extended from October 1999 to December 2005.
Four groups of patients were studied: (1) those with at least
one ATN admission, but no admissions for MI or PNE (ATN);
(2) those with one or more ARF admissions, but no ATN, PNE,
or MI admission (ARF); (3) those with MI or PNE admissions but
no ARF or ATN admissions (CON); and (4) patients with one
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of the above admission diagnoses who also had CKD, who were
removed from the above three groups and examined separately.
Patients were labeled as CKD if they entered CKD stage 3 (CKD-3),
CKD-4, or CKD-5, or started chronic dialysis before the first
ATN/ARF/MI/PNE admission date, or if they had a mean eGFR
o60 ml/min per 1.73 m2 during the year before this date (or if eGFR
was missing or if they had a mean SCX1.5 mg/dl). Patients with
other combinations of diagnoses (for example, ATN and MI) were
excluded along with patients with no SC tests during the year before
diagnosis.
Variables
For each patient, we gathered every SC date and value recorded
during the study period. For each SC value, we calculated eGFR
using the Modification by Diet of Renal Disease equation.39 We
obtained the date of death from the VA BIRLS Death File (updated
weekly with records from the Social Security Administration, SSA).
SC values below 0.4 or above 25 mg/dl were coded as missing. eGFR
values above 140 were recoded to 140 ml/min per 1.73 m2. CKD-3,
-4, or -5 entries were defined as the first day when eGFR dropped
below a threshold, after which it never rose above that level for
that patient. Thresholds were 60, 30, and 15 ml/min per 1.73 m2,
respectively, for CKD-3, -4, and -5. Presence of diabetes mellitus
(ICD-9 code 250.xx) was noted if diagnosis occurred during any
outpatient visit or inpatient admission before the ATN/ARF/MI/
PNE diagnosis date. Chronic dialysis was defined as having at least
13 outpatient dialysis visits within a 60-day period. The start date
for chronic dialysis was defined as the date of the first of these 13
visits. Diagnosis date was the date of the first PNE or MI admission
for CON patients, or the first ARF or ATN admission for ARF and
ATN patients. Outcome variables included CKD-4 entry, death, and
a combined end point, including chronic dialysis, CKD-4, or death,
whichever came first.
Data analysis
To examine diagnostic accuracy, we assessed the severity of AKI for
each group from admission to 30 days later by RIFLE criteria40 and
by peak SC. To determine whether the ATN, ARF, CON, and CKD
groups had similar temporal SC trends, for each group, we
computed the mean and peak SC values for 1 year before diagnosis,
and at 0 to 30 days, 31 to 90 days, 91 to 365 days, and 4365 days
after diagnosis. Repeated-measures analysis of variance was used to
assess changes in mean SC and eGFR values over time within and
between groups. Interactions were examined to assess the differ-
ential rate of change of renal function between groups over time. All
analyses were performed using both SC and eGFR measures (using
Proc GLM in SAS version 9.1, Cary, NC).
To address whether ATN, ARF, CKD, and CON groups differed
in the rate at which their kidney function declined, we examined the
differences in survival time (time from diagnosis to CKD-4) across
diagnostic groups, using both Kaplan–Meier and Cox regression
procedures (Proc Lifetest and PHREG in SAS 9.1). Covariates
included age, race, gender, presence of diabetes, diagnosis date,
mean preadmission SC and albumin levels, and whether they were
admitted to a teaching hospital (defined as complexity level 1, with
45 residency training slots). Diagnostic and ethnic groups were
coded as dummy variables to obtain risk estimates. Patients were
censored at death or at 60 months after their diagnosis date,
whichever came first. CKD patients who entered CKD-4 before their
diagnosis date were excluded from the CKD-4 analysis. To account
for nonproportional hazards, we included an interaction term for
diagnosis variables by time, when appropriate. If subjects in one
diagnostic group received fewer SC tests after initial admission, it is
possible that we were unable to pick up their actual date of entry
into CKD-4. To test whether this occurred, we examined the
percentage of subjects in each group with SC readings and the mean
number of SC readings during the periods 0–30, 31–90, 91–365, and
X366 days after admission. We also repeated the survival analysis
for time from diagnosis to development of CKD-4, removing
subjects who were missing SC readings at any of these time periods.
We examined the differences between groups with regard to time
from diagnosis to death, and time to the combined end point, using
the same covariates and methodology.
Data are presented as mean±s.d. Po0.05 was considered as
significant, unless otherwise specified. All data were deidentified
using scrambled social security numbers. The study was approved by
the Institutional Review Board of the Washington DC VA Medical
Center.
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